Efficacy of metformin and sibutramine therapy in patients with infertility associated with metabolic syndrome

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The increasing interest of the scientific medical community in the problem of metabolic syndrome (MS), its timely diagnosis and treatment, is associated with a steady increase in the incidence of MS. The most alarming thing is that the majority of patients are people of active work-related and reproductive age. According to scientists, the frequency of MS is expected to increase by 50% in the next 20 years, which means that in the absence of effective prevention and treatment of MS, industrialized countries risk facing a social and demographic catastrophe. In addition to non-drug treatments for MS (diet, exercise, etc.), metformin and sibutramine are recognized as extremely important drugs of choice in the medical treatment of MS.

全文:

受限制的访问

作者简介

М. Martina

Palliative Care Center of Department of Health Care of Moscow

编辑信件的主要联系方式.
Email: rchilova@gmail.com
俄罗斯联邦, Moscow

R. Chilova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: rchilova@gmail.com
ORCID iD: 0000-0001-6331-3109

Professor, MD

俄罗斯联邦, Moscow

Е. Sokova

Scientific Center for the Examination of Medical Products, Ministry of Health of Russia

Email: rchilova@gmail.com
ORCID iD: 0000-0002-6389-2099

Associate Professor, Candidate of Medical Sciences

俄罗斯联邦, Moscow

S. Maslov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: rchilova@gmail.com
ORCID iD: 0009-0007-1215-1059
俄罗斯联邦, Moscow

М. Poznyak

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: rchilova@gmail.com
ORCID iD: 0009-0006-8217-0784
俄罗斯联邦, Moscow

G. Sevastyanov

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: rchilova@gmail.com
俄罗斯联邦, Moscow

参考

  1. Ибрагимова Н.А., Гальченко О.Е., Тарасов А.А. и др. Метаболический синдром: современные подходы к фармакотерапии. Лекарственный вестник. 2012; 6 (5): 43–6 [Ibragimova N.A., Galchenko O.E., Tarasov A.A. et al. Metabolic syndrome: modern approaches to pharmacotherapy. Lekarstvennyi vestnik. 2012; 6 (5): 43-6 (in Russ.)].
  2. Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. и др. Метаболический синдром: история развития, основные критерии диагностики. Рациональная терапия в кардиологии. 2018; 14 (5): 757–64 [Belenkov Yu.N., Privalova E.V., Kaplunova V.Y. et al. Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria. Rational Pharmacotherapy in Cardiology. 2018; 14 (5): 757–64 (in Russ.)]. doi: 10.20996/1819-6446-2018-14-5-757-764
  3. Bourassa K., Knowles L., Sbarra D. et al. Absent but Not Gone Interdependence in Couples’ Quality of Life Persists After a Partner’s Death. Psychol Sci. 2016; 27 (2): 270–81. doi: 10.1177/0956797615618968
  4. Grand P.J. Beneficial effects of metformin on hemostasis and vascular function in man. Diabetes Metab. 2003; 29 (4 Pt 2): 6S45–52. doi: 10.1016/s1262-3636(03)72787-6
  5. Charles M.A., Morange P., Eschwege E. et al. Effects of weight change and metformin on fibrolysis and the von Willebrand factor in obese nondiabetic subjects. The BIGPRO1 Study. Diabetes Care. 1998; 21 (11): 1967–75. doi: 10.2337/diacare.21.11.1967
  6. Gast G.-C.M., Grobee D.E., Pop V.J.M. et al. Vasomotor symptoms are associated with a lower bone mineral density. Menopause. 2009; 16 (2): 231–8. doi: 10.1097/gme.0b013e318185e25b
  7. Budak E., Fernandez Sanchez M., Bellver J. et al. Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3–36 with the reproductive system. Fertil Steril. 2006; 85 (6): 1563–81. doi: 10.1016/j.fertnstert.2005.09.065
  8. Mitchell M., Armstrong D.T., Robker R.L. Adipokines: implications for female fertility and obesity. Reproduction. 2005; 130 (5): 583–97. doi: 10.1530/rep.1.00521
  9. Bellemare V., Laberge P., No L.S. et al. Differential estrogenic 17beta-hydroxysteroid dehydrogenase activity and type 12 17beta-hydroxysteroid dehydrogenase expression levels in preadipocytes and differentiated adipocytes. J Steroid Biochem Mol Biol. 2009; 114 (3–5): 129–34. doi: 10.1016/j.jsbmb.2009.01.002
  10. Гордеева А.Ю., Ткачева М.В., Чилова Р.А. и др. Лечение пациенток с бесплодием, ассоциированным с метаболическим синдромом, и его влияние на качество жизни. РМЖ. 2017; 1: 41–5 [Gordeeva A.Yu., Tkacheva M.V., Chilova R.A. et al. The treatment of infertility associated with metabolic syndrome and its effect on the quality of life. RMJ. 2017; 1: 41–5 (in Russ.)].
  11. Lautatzis M., Goulis D., Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism. 2013; 62 (11): 1522–34. doi: 10.1016/j.metabol.2013.06.006

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2024
##common.cookie##